Targeting METTL3 or IGF2BP2, either through genetic knockdown or pharmacological inhibition, could decrease the stability of GAS5, leading to reduced expression of this oncogenic lncRNA and subsequent inhibition of HCC growth. The gene discussed is IGF2BP2; the disease is hepatocellular carcinoma.